AU2022362310A1 - Prodrugs of axitinib - Google Patents

Prodrugs of axitinib Download PDF

Info

Publication number
AU2022362310A1
AU2022362310A1 AU2022362310A AU2022362310A AU2022362310A1 AU 2022362310 A1 AU2022362310 A1 AU 2022362310A1 AU 2022362310 A AU2022362310 A AU 2022362310A AU 2022362310 A AU2022362310 A AU 2022362310A AU 2022362310 A1 AU2022362310 A1 AU 2022362310A1
Authority
AU
Australia
Prior art keywords
compound
oco
certain embodiments
och
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022362310A
Other languages
English (en)
Inventor
Rami EL-HAYEK
Peter Jarrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocular Therapeutix Inc
Original Assignee
Ocular Therapeutix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocular Therapeutix Inc filed Critical Ocular Therapeutix Inc
Publication of AU2022362310A1 publication Critical patent/AU2022362310A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022362310A 2021-10-15 2022-10-14 Prodrugs of axitinib Pending AU2022362310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163255998P 2021-10-15 2021-10-15
US63/255,998 2021-10-15
PCT/US2022/046750 WO2023064578A1 (en) 2021-10-15 2022-10-14 Prodrugs of axitinib

Publications (1)

Publication Number Publication Date
AU2022362310A1 true AU2022362310A1 (en) 2024-04-11

Family

ID=85987895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022362310A Pending AU2022362310A1 (en) 2021-10-15 2022-10-14 Prodrugs of axitinib

Country Status (8)

Country Link
US (1) US20250092013A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416132A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537839A (cg-RX-API-DMAC7.html)
CN (1) CN118119599A (cg-RX-API-DMAC7.html)
AU (1) AU2022362310A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232086A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003968A (cg-RX-API-DMAC7.html)
WO (1) WO2023064578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119947722A (zh) * 2022-10-14 2025-05-06 视尔普斯眼科公司 前药、制剂及其方法
JP2026520094A (ja) 2023-04-11 2026-06-22 オキュラ セラピューティクス，インコーポレイテッド アキシチニブ多形ｉｖを含む眼科インプラント

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
WO2016183296A1 (en) * 2015-05-12 2016-11-17 Incept, Llc Drug delivery from hydrogels
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN106336397A (zh) * 2015-07-07 2017-01-18 郭明山 一种作为治疗眼科疾病的新化合物
WO2021035360A1 (en) * 2019-08-30 2021-03-04 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of the tyrosine kinase inhibitor for treating cancer
US12637441B2 (en) * 2019-08-30 2026-05-26 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of the tyrosine kinase inhibitor for treating cancer
CN112442010B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 一类前药化合物及其在治疗癌症方面的应用
CA3171563A1 (en) * 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor

Also Published As

Publication number Publication date
MX2024003968A (es) 2024-04-29
EP4416132A4 (en) 2025-09-03
US20250092013A1 (en) 2025-03-20
EP4416132A1 (en) 2024-08-21
CA3232086A1 (en) 2023-04-20
WO2023064578A1 (en) 2023-04-20
CN118119599A (zh) 2024-05-31
JP2024537839A (ja) 2024-10-16

Similar Documents

Publication Publication Date Title
KR102039468B1 (ko) 의료용 유기젤 방법 및 조성물
JP6342716B2 (ja) 便利に移植可能な徐放性薬物処方物
CN108601725A (zh) 形状改变的药物递送装置和方法
US20160106587A1 (en) Ocular gels or hydrogels and microinjectors
CN111481513A (zh) 缓释微球药物递送系统及其制备方法
KR20170117384A (ko) 히드로겔 약물 전달 임플란트
US20250092013A1 (en) Prodrugs of axitinib
EP2825206A1 (en) Controlled release formulations for the delivery of hif-1 inhibitors
MXPA03008498A (es) Procesamiento en dos fases de polimeros termosensibles para uso como biomateriales.
JP2010519183A (ja) 生理溶液の溶出のためのタンパク質の沈殿を用いる重合
US20180008718A1 (en) Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
WO2017015616A1 (en) Ocular protein delivery
US20240042713A1 (en) Extruded ocular inserts or implants and methods thereof
AU2023360240A1 (en) Prodrugs, formulations and methods thereof
JP2022501365A (ja) ドラッグデリバリーのための多孔質生体吸収性放射線不透過性塞栓ミクロスフェア
US12453724B2 (en) Ocular implant containing a tyrosine kinase inhibitor
CN1665550A (zh) 输送和释放药物活性剂的植入物及其制备方法
US20230241055A1 (en) Hydrophilic Degradable Microspheres for Delivering Buprenorphine
JP2025526731A (ja) 持続的薬物送達のためのオルガノゲル、その調製及び使用の方法
HK40115702A (en) Single solution hydrogels with covalent bonding formed in situ, composition design and medical procedures using the hydrogels
WO2026107180A1 (en) Implant injector device
CN118591369A (zh) 挤出式眼部插入物或植入物及其方法
HK1261346A1 (en) Shape changing drug delivery devices and methods